Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hemay005 in Behçet Disease
NCT04609397Phase 2Terminated
- Sponsor
- Tianjin Hemay Biotech
- Start
- Nov 2020
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of mufemilast in Behçet's disease (BD) (3 arms), sponsored by Tianjin Hemay Biotech. Primary endpoint: Efficacy of Hemay005 at 12 weeks. Started Nov 2020; status: terminated.
02
Drugs
mufemilast
03
Conditions
Behçet's disease (BD)
Beyond the preview
Go deeper on NCT04609397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04609397.